Research Abstracts, Phase 2 Results, and Market Availability of Formulations and Treatments- Research Report on Teva, Forest,

 Research Abstracts, Phase 2 Results, and Market Availability of Formulations
 and Treatments- Research Report on Teva, Forest, Pharmacyclics, Cubist, and
                                 Dr. Reddy's

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, June 19, 2013

NEW YORK, June 19, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Teva
Pharmaceutical Industries Ltd (NYSE: TEVA), Forest Laboratories, Inc. (NYSE:
FRX), Pharmacyclics, Inc. (NASDAQ: PCYC), Cubist Pharmaceuticals, Inc.
(NASDAQ: CBST), and Dr. Reddy's Laboratories Limited (NYSE: RDY). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Teva Pharmaceuticals Industries Ltd Research Report

On June 14, 2013, Teva Pharmaceuticals Industries Ltd (Teva) announced that
the Company will present a number of abstracts during the 17th Annual
International Congress of Parkinson's Disease and Movement Disorders, held in
Sydney, Australia from June 16 to June 20, 2013. The Company affirmed that
these presentations will reflect Teva's ongoing commitment to Parkinson's
Disease (PD) research and underscore the potential of AZILECT as a treatment
modality for PD. "We are committed to driving advances in research to help
address the treatment needs of those impacted by neurological conditions,"
said Michael Hayden, MD, President of Global R&D and Chief Scientific Officer
at Teva. The Full Research Report on Teva Pharmaceuticals Industries Ltd -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Forest Laboratories,Inc. Research Report

On June 13, 2013, Forest Laboratories, Inc. (Forest) announced the
availability of NAMENDA XR (memantine hydrochloride) once-daily formulation,
in pharmacies throughout the United States. NAMENDA XR is approved by the FDA
for the treatment of moderate to severe dementia of the Alzheimer's type. The
efficacy and safety of the formulation was established in a randomized,
double-blind, placebo-controlled trial of 677 outpatients on a stable dose of
acetylcholinesterase inhibitors (AChEI). The results of the study demonstrated
statistically significant improvement in cognition and global function for
patients treated with NAMENDA XR 28 mg plus an AChEI compared to placebo plus
an AChEI. "The NAMENDA XR study supports the existing body of evidence that
memantine provides cognitive and global benefits in patients with moderate to
severe Alzheimer's disease either alone or with an AChEI," said Dr. Marco
Taglietti, President of Forest Research Institute. The Full Research Report on
Forest Laboratories, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:


Pharmacyclics,Inc. Research Report

On June 16, 2013, Pharmacyclics, Inc. (Pharmacyclics) announced the results of
two separate Phase 2 studies suggesting that ibrutnib showed efficacy when
used as a monotherapy in patients with relapsed/refractory mantle cell
lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL). The Company sponsored
both studies and is jointly developing ibrutnib with Janssen Research &
Development, LLC. The findings at EHA for patients with MCL or DLBCL expand on
the results reported by investigators in 2012. Among patients with
relapsed/refractory MCL, ibrutnib achieved an overall response rate (ORR) of
68%, including a complete response (CR) of 21% where all signs of cancer are
gone, and a partial response (PR) of 47%. In the second study among
relapsed/refractory DLBCL patients, investigators examined whether ibrutinib
would be more active in the Activated B-cell-like (ABC) subtype of DBCL
compared to those with the Germinal Center B-Cell-like (GCB) subtype. Results
revealed that patients with the ABC subtype showed a preferential response to
ibrutinib monotherapy compared to those with the GCB subtype, with ORR
response rate of 41% vs. 5%, respectively. The Full Research Report on
Pharmacyclics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:


Cubist Pharmaceuticals,Inc. Research Report

On June 13, 2013, Cubist Pharmaceuticals, Inc. (Cubist) announced the
appointment of Dr. Lorianne Masuoka as Chief Medical Officer and Senior Vice
President of Clinical Development and Medical Affairs. With the new
appointment, Dr. Masuoka will lead the strategy, development, and
implementation of the Company's global clinical programs, while overseeing
Clinical Research, Medical Affairs, Clinical Operations, Biostatistics, Data
Management, and Pharmacovigilance. "Dr. Masuoka brings to Cubist a great blend
of medical and scientific leadership, diversity of therapeutic area
experience, and global management skills," said Steven Gilman, Ph.D.,
Executive Vice President of Research and Development and Chief Scientific
Officer of Cubist. Dr. Masuoka has more than 25 years of global medical and
development experience. Previously, she has served in many roles, including as
Senior Vice President and Chief Medical Officer at Nektar Therapeutics, VP of
Clinical Development at Fiveprime Therapeutics, and Director of Clinical
Development at Chiron. The Full Research Report on Cubist Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:


Dr. Reddy's Laboratories Limited Research Report

On June 3, 2013, Dr. Reddy's Laboratories Limited (Dr. Reddy's) and Fujifilm
Corporation (Fujifilm) announced the termination of their Memorandum of
Understanding (MoU) to enter into an exclusive partnership in the generic
drugs business for the Japanese market and to establish a joint venture in
Japan. The MoU was signed on July 28, 2011, based on which the two Companies
had conducted detailed studies on the establishment of a joint venture for
developing and manufacturing generic drugs in Japan. However, the Company
stated that as Fujifilm is realigning its long-term growth strategy, both
Companies have agreed on terminating the MoU. "Unfortunately, we will not be
able to partner with Fujifilm specifically for generic formulations business
in Japan. However, I want to reinforce our commitment towards a planned entry
into Japan to bring affordable and innovative drugs to more patients
worldwide," said GV Prasad, Chairman and CEO of Dr. Reddy's. The Full Research
Report on Dr. Reddy's Laboratories Limited - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: []



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquires, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports
Press spacebar to pause and continue. Press esc to stop.